Antimicrobial Susceptibility Testing (AST): Overview of Methods and Clinical Relevance

Antimicrobial susceptibility testing (AST) determines whether a bacterial isolate is susceptible, intermediate, or resistant to specific antimicrobial agents. This laboratory procedure guides treatment decisions for infected patients, supports antimicrobial stewardship programs, and generates surveillance data that track resistance trends in communities and healthcare facilities. For laboratory students, technicians, researchers, and diagnostic professionals, understanding the strengths and limitations of each AST method is essential for producing reliable results that clinicians can trust. This article compares disk diffusion, broth microdilution, agar dilution, and automated systems, with practical guidance on method selection, quality control, interpretation, and documentation.

AST is a critical function of the clinical microbiology laboratory and is essential for optimizing care of patients with infectious diseases, monitoring antimicrobial resistance trends, and informing public health initiatives (Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists). The choice of method depends on laboratory resources, workload, organism type, antimicrobial agents being tested, and the clinical questions that need answers. Each method has distinct operational requirements, turnaround times, and interpretive frameworks that laboratory professionals must understand before implementation.

At a Glance

The table below summarizes the main AST methods, their core principles, practical considerations, and typical applications in clinical and research laboratories.

The harmonization of breakpoints across Europe through the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the ongoing updates by the Clinical and Laboratory Standards Institute (CLSI) have improved consistency in susceptibility reporting. Harmonized breakpoints and methods help avoid different reports of susceptibility for the same isolate in different countries and enable more reliable comparison of resistance rates in surveillance studies (Antimicrobial susceptibility testing breakpoints and methods from BSAC to EUCAST). Laboratories must verify that their interpretive criteria reflect the most current breakpoint revisions from the relevant standards organization.

Core Principles of Antimicrobial Susceptibility Testing

AST measures the in vitro activity of an antimicrobial agent against a bacterial isolate under standardized conditions. The fundamental assumption is that in vitro susceptibility correlates with clinical outcome when the patient receives an appropriate dose of the antimicrobial. This correlation depends on pharmacokinetic and pharmacodynamic factors that translate laboratory results into clinical predictions.

Minimum Inhibitory Concentration

The minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial that prevents visible growth of the organism under defined test conditions. MIC values are expressed in micrograms per milliliter (µg/mL) and provide a quantitative measure of antimicrobial activity. Broth microdilution and agar dilution produce direct MIC values, while disk diffusion produces zone diameters that are correlated with MIC breakpoints through interpretive criteria.

MIC values alone do not determine clinical decisions. Breakpoints, which are established by organizations such as CLSI and EUCAST, categorize MIC values into susceptible, intermediate, and resistant categories. These breakpoints are revised as new resistance mechanisms emerge, new antimicrobial agents are developed, and new clinical data become available. The emergence of new resistance mechanisms, the development of new antimicrobial agents, and the generation of new data require updates and revisions to established methods and breakpoints (Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists).

Breakpoint Interpretation

Breakpoints define the MIC value or zone diameter that separates susceptible from resistant organisms. Susceptible means the organism is likely to respond to treatment with the recommended dose of the antimicrobial. Intermediate means the organism may respond at higher doses or in body sites where the drug concentrates. Resistant means the organism is unlikely to respond to treatment with that antimicrobial.

Using outdated breakpoints can lead to considerable overestimation of susceptibility, which can result in ineffective treatments. A retrospective analytical study of 9,279 bacterial isolates found significant misclassification when outdated CLSI breakpoints were applied, particularly for aminoglycosides against Enterobacterales and for piperacillin-tazobactam and tobramycin against Pseudomonas aeruginosa (Impact of Outdated Clinical and Laboratory Standards Institute (CLSI) Breakpoint Implementation on Antimicrobial Susceptibility Interpretation: A Retrospective Analytical Study). Laboratories must track breakpoint revisions and update their interpretive criteria promptly to avoid reporting errors.

Standardization and Reference Methods

Standardized methods ensure that results are reproducible within a laboratory and comparable across laboratories. CLSI and EUCAST publish detailed protocols that specify inoculum preparation, media composition, incubation conditions, and quality control organisms. The World Health Organization Laboratory Quality Management System Handbook provides guidance on implementing quality systems in laboratories, including the standardization of testing procedures (Laboratory Quality Management System Handbook).

Reference methods serve as the gold standard against which other methods are evaluated. Broth microdilution is the reference method for many organism-antimicrobial combinations. When a laboratory adopts a new method or a new antimicrobial panel, the method must be validated against the reference method to ensure acceptable categorical agreement and acceptable rates of major errors and very major errors.

Disk Diffusion Method

Disk diffusion, also known as the Kirby-Bauer method, is one of the most widely used AST methods in clinical laboratories. The method involves placing paper discs impregnated with standardized concentrations of antimicrobial agents onto an agar plate that has been inoculated with a standardized suspension of the test organism. After incubation, the diameter of the zone of inhibition around each disc is measured and interpreted using breakpoint tables.

Procedure and Materials

The disk diffusion method requires Mueller-Hinton agar, which is the recommended medium for most non-fastidious organisms. The agar depth must be consistent, typically 4 millimeters, because zone diameters are affected by agar depth. The inoculum is prepared by suspending isolated colonies in sterile saline or broth to a turbidity equivalent to a 0.5 McFarland standard. The inoculum is applied to the agar surface using a swab, and the plates are allowed to dry before discs are applied.

Discs must be stored according to manufacturer instructions to maintain potency. Expired discs or discs stored improperly can produce inaccurate zone diameters. The Clinical and Laboratory Standards Institute publishes performance standards for antimicrobial susceptibility testing that include quality control ranges for each antimicrobial disc and test organism combination (Performance standards for antimicrobial susceptibility testing).

Zone Diameter Measurement and Interpretation

After incubation for 16 to 24 hours at 35 degrees Celsius, the diameter of each zone of inhibition is measured in millimeters. The measurement should include the entire zone, including the disc. For organisms that swarm or produce faint growth, the zone edge may be difficult to define, and the measurement should be taken at the point of obvious inhibition.

Zone diameters are interpreted using breakpoint tables published by CLSI or EUCAST. The interpretive categories are susceptible, intermediate, and resistant. Some organism-drug combinations require special interpretive considerations, such as reading the zone edge for penicillin against staphylococci. In a study of Staphylococcus lugdunensis, disc diffusion with zone edge interpretation was more accurate and specific than automated broth microdilution for detecting penicillin and oxacillin resistance (Antimicrobial Susceptibility Testing for Staphylococcus lugdunensis).

Factors Affecting Disk Diffusion Results

Several factors can affect the accuracy and reproducibility of disk diffusion results. The inoculum density must be standardized because too heavy an inoculum produces smaller zones and too light an inoculum produces larger zones. The agar depth affects the rate of antimicrobial diffusion, with deeper agar producing smaller zones. The incubation temperature and atmosphere must be controlled, and the timing of zone measurement must be consistent.

The composition of the medium can also affect results. Mueller-Hinton agar is recommended because it supports the growth of most non-fastidious organisms and produces reproducible zone diameters. Supplements may be required for fastidious organisms, such as blood for Streptococcus species or Haemophilus test medium for Haemophilus influenzae. Factors affecting the antimicrobial susceptibility testing of bacteria by the disc diffusion method include inoculum size, medium composition, disc content, incubation conditions, and the method of zone measurement (Factors affecting the antimicrobial susceptibility testing of bacteria by disc diffusion method).

Broth Microdilution Method

Broth microdilution is a quantitative method that determines the MIC of an antimicrobial against a bacterial isolate. The method uses microtiter plates with 96 wells, each containing a different concentration of the antimicrobial agent in broth medium. The wells are inoculated with a standardized bacterial suspension, and after incubation, the lowest concentration that inhibits visible growth is recorded as the MIC.

Procedure and Materials

Broth microdilution requires cation-adjusted Mueller-Hinton broth for most non-fastidious organisms. The antimicrobial agents are prepared in serial twofold dilutions, typically ranging from 0.03 to 64 µg/mL depending on the agent and the expected MIC distribution. The inoculum is prepared to a final concentration of approximately 5 x 10^5 colony-forming units per milliliter in each well.

The plates are incubated at 35 degrees Celsius for 16 to 24 hours. The MIC is read as the lowest concentration of the antimicrobial that completely inhibits visible growth of the organism. The endpoint is determined by comparing the test wells with a growth control well that contains no antimicrobial.

Advantages and Limitations

Broth microdilution provides quantitative MIC values, which are useful for guiding therapy in infections where the MIC influences the antimicrobial dose or route of administration. The method is reproducible and can be standardized across laboratories. It is also adaptable to automation, with commercial systems using broth microdilution as the basis for their testing platforms.

The main limitations of broth microdilution are the labor and materials required for preparing the dilution series and the potential for errors in dilution preparation. The method is also less flexible than disk diffusion for testing custom panels of antimicrobial agents. For laboratories that test large numbers of isolates, the cost of microtiter plates and reagents can be substantial.

Reference Method Status

Broth microdilution is the reference method for many organism-antimicrobial combinations and is used to validate other AST methods. The Assay Guidance Manual from the National Center for Advancing Translational Sciences provides detailed protocols for antimicrobial susceptibility testing in research settings, including broth microdilution procedures (Assay Guidance Manual). Research laboratories developing new antimicrobial agents or testing unusual organisms often use broth microdilution as the primary method.

Agar Dilution Method

Agar dilution is a quantitative method that incorporates serial dilutions of an antimicrobial agent into agar plates. Each plate contains a specific concentration of the antimicrobial, and multiple isolates can be tested on each plate using a replicator device that applies standardized inocula to the agar surface.

Procedure and Materials

Agar dilution requires preparation of agar plates containing twofold serial dilutions of the antimicrobial agent. The antimicrobial is added to molten agar at the appropriate temperature, and the plates are poured and allowed to solidify. The plates are then inoculated with a replicator that transfers a standardized number of organisms to each plate.

After incubation, the MIC is recorded as the lowest concentration of the antimicrobial that inhibits visible growth of the organism. Agar dilution is efficient for testing large numbers of isolates against a single antimicrobial agent, making it useful for surveillance studies and research applications.

Comparison with Broth Microdilution

Agar dilution and broth microdilution produce comparable MIC values for most organism-antimicrobial combinations. Agar dilution has the advantage of allowing visual inspection of colony morphology and contamination, which can be useful for detecting mixed cultures. However, agar dilution is more labor-intensive for preparing plates and is less adaptable to automation.

The choice between agar dilution and broth microdilution depends on the laboratory's workload and resources. Laboratories that test large numbers of isolates for surveillance purposes may prefer agar dilution, while clinical laboratories that test individual patient isolates may prefer broth microdilution or disk diffusion.

Automated Susceptibility Testing Systems

Automated systems combine growth detection with interpretive software to provide rapid AST results. These systems use broth microdilution or other growth detection principles in a closed cartridge or panel format. The systems monitor bacterial growth in the presence of antimicrobial agents and automatically determine MIC values and interpretive categories.

Commercial Platforms

Several commercial automated systems are available for clinical laboratories. These systems offer standardized panels of antimicrobial agents, automated inoculation and reading, and integrated data management for reporting and surveillance. The systems vary in their organism coverage, antimicrobial panels, and turnaround times.

Automated systems can produce results in 4 to 16 hours, depending on the organism and the system. This rapid turnaround time is valuable for patients with serious infections, particularly bloodstream infections where timely antimicrobial therapy is critical. Rapid AST methods for blood cultures can impact clinical outcomes of patients with bloodstream infections (Rapid Antimicrobial Susceptibility Testing Methods for Blood Cultures and Their Clinical Impact).

Validation and Limitations

Automated systems must be validated against reference methods before implementation. The validation should include a sufficient number of isolates to assess categorical agreement, major errors, and very major errors. The system's performance may vary by organism and antimicrobial agent, and laboratories should be aware of known limitations.

In the study of Staphylococcus lugdunensis, the Vitek 2 automated system overestimated penicillin and oxacillin resistance compared with disc diffusion and PCR results, with a major error rate of 14.2% for penicillin susceptibility testing (Antimicrobial Susceptibility Testing for Staphylococcus lugdunensis). This finding illustrates the importance of understanding the limitations of automated systems for specific organism-drug combinations and confirming unusual results with alternative methods.

Integration with Laboratory Workflow

Automated systems can be integrated with laboratory information systems to streamline result reporting and data management. The systems can generate cumulative antibiograms that summarize resistance rates for specific organisms and patient populations. This integration supports antimicrobial stewardship programs by providing timely and accurate susceptibility data.

The digital infrastructure for AST and surveillance requires effective laboratory information systems that capture culture and AST data, standardize AST panels, and generate cumulative antibiograms. A study at a teaching hospital in Rwanda identified critical gaps in laboratory information systems, including low capture rates for culture observation and AST data, no standardization of AST panels, and limited cumulative antibiogram generation (Digital Infrastructure for Antimicrobial Susceptibility Testing and Surveillance: A CLSI and EUCAST-Based Model for Resource-Limited Settings).

Method Selection and Laboratory Workflow

Selecting the appropriate AST method requires consideration of laboratory resources, workload, organism types, and clinical needs. The method must produce reliable results within a timeframe that supports clinical decision-making while remaining cost-effective for the laboratory.

Workload and Throughput Considerations

Laboratories with high testing volumes may benefit from automated systems that process multiple specimens simultaneously with minimal hands-on time. Smaller laboratories with lower volumes may find disk diffusion more cost-effective, as it requires minimal equipment and can accommodate flexible antimicrobial panels.

The turnaround time for AST results is an important consideration. Conventional phenotypic methods require 16 to 24 hours for growth and antimicrobial response, which delays the availability of results. Rapid AST methods that reduce detection time can minimize treatments with empirical broad-spectrum antibiotics and combat the further spread of antimicrobial resistance (Microfluidic Systems for Antimicrobial Susceptibility Testing).

Organism-Specific Considerations

The choice of AST method may depend on the organism being tested. Fastidious organisms, anaerobes, and organisms with unusual growth requirements may require specialized methods or media. Antimicrobial susceptibility testing of anaerobic bacteria is not routinely performed in many laboratories, and the testing is highly disarrayed, with limited literature available (Antimicrobial susceptibility testing of anaerobic bacteria: In routine and research).

For organisms that grow slowly or produce atypical colony morphology, broth microdilution may be more reliable than disk diffusion. For organisms that swarm across the agar surface, such as Proteus species, disk diffusion zones may be difficult to measure, and broth microdilution may be preferred.

Cost and Resource Assessment

The cost of AST methods includes reagents, consumables, equipment, and personnel time. Disk diffusion requires minimal equipment but consumes significant personnel time for plate preparation, inoculation, and zone measurement. Broth microdilution requires more reagents but can be partially automated. Automated systems require significant capital investment but reduce personnel time and improve workflow efficiency.

Laboratories should conduct a cost analysis that includes the full cost of each method, including quality control, maintenance, and troubleshooting. The analysis should also consider the cost of errors, including the clinical consequences of misclassified susceptibility results.

Quality Control and Assurance

Quality control is essential for ensuring the accuracy and reliability of AST results. Laboratories must implement quality control procedures that monitor the performance of media, reagents, equipment, and personnel.

Quality Control Organisms

Quality control organisms with known susceptibility patterns are tested alongside clinical isolates to verify that the testing system is performing correctly. The quality control organisms are selected based on their expected zone diameters or MIC values for each antimicrobial agent. The results must fall within established quality control ranges for the test to be considered valid.

The Clinical and Laboratory Standards Institute publishes quality control ranges for each antimicrobial agent and test organism combination (Performance standards for antimicrobial susceptibility testing). Laboratories must test quality control organisms on a regular schedule, typically daily or weekly depending on the method and the laboratory's quality system.

Internal Quality Control

Internal quality control includes the daily testing of quality control organisms, monitoring of media and reagent performance, and verification of equipment calibration. The laboratory must document quality control results and investigate any results that fall outside the acceptable ranges.

The World Health Organization Laboratory Quality Management System Handbook provides guidance on implementing internal quality control procedures, including the selection of quality control organisms, the frequency of testing, and the documentation of results (Laboratory Quality Management System Handbook).

External Quality Assessment

External quality assessment programs, also known as proficiency testing, evaluate the laboratory's performance by sending unknown specimens for testing. The laboratory's results are compared with those of other laboratories, and any discrepancies are investigated. Participation in external quality assessment programs is required for laboratory accreditation and provides an objective measure of testing quality.

External quality assessment programs are particularly important for AST because they evaluate the laboratory's ability to correctly categorize isolates as susceptible, intermediate, or resistant. Discrepancies may indicate problems with media preparation, inoculum standardization, breakpoint interpretation, or result reporting.

Interpretation and Reporting

The interpretation of AST results requires knowledge of breakpoints, organism-specific considerations, and clinical context. The laboratory must report results in a format that is useful to clinicians and that supports antimicrobial stewardship.

Categorical Interpretation

AST results are reported as susceptible, intermediate, or resistant based on the breakpoints established by CLSI or EUCAST. The interpretive categories guide clinical decision-making, with susceptible results indicating that the antimicrobial is likely to be effective and resistant results indicating that it is unlikely to be effective.

The choice of breakpoint standard is important because CLSI and EUCAST may use different breakpoints for the same organism-antimicrobial combination. Laboratories must select one standard and apply it consistently. The harmonization of breakpoints across Europe has reduced discrepancies between countries, but differences between CLSI and EUCAST remain for some agents (Antimicrobial susceptibility testing breakpoints and methods from BSAC to EUCAST).

Selective Reporting

Selective reporting, also known as cascade reporting, involves reporting only the antimicrobial agents that are most appropriate for the clinical context. This practice reduces the selective pressure for antimicrobial resistance by limiting the use of broad-spectrum agents when narrower agents are effective.

For example, for a urinary tract infection isolate, the laboratory may report only the antimicrobials that achieve therapeutic concentrations in the urine. For a bloodstream infection isolate, the laboratory may report the antimicrobials that achieve therapeutic concentrations in the blood. Selective reporting requires collaboration between the laboratory and the antimicrobial stewardship program.

Antibiogram Generation

Cumulative antibiograms summarize the susceptibility patterns of organisms isolated in the laboratory over a defined period, typically one year. Antibiograms are used to guide empirical antimicrobial therapy, monitor resistance trends, and identify emerging resistance problems.

Age-specific antibiograms can reveal differences in susceptibility patterns between patient populations. A study of bacterial meningitis pathogens found significant differences in ciprofloxacin susceptibility between age groups, with susceptibility decreasing from 82% in patients under 18 years to 75% in patients over 50 years (Age-Specific Antibiograms for Bacterial Meningitis Pathogens Based on Isolates Collected in a Community Laboratory). These findings support the use of age-specific antibiograms for guiding empirical therapy.

Common Failure Patterns and Troubleshooting

Laboratories encounter a range of problems in AST that can compromise result accuracy. Recognizing common failure patterns and implementing corrective actions is essential for maintaining testing quality.

Inoculum Standardization Errors

Inoculum density is a critical variable in AST. An inoculum that is too heavy produces smaller zones in disk diffusion and higher MIC values in broth microdilution, potentially overestimating resistance. An inoculum that is too light produces larger zones and lower MIC values, potentially overestimating susceptibility.

The inoculum should be prepared from isolated colonies using a standardized method, such as the direct colony suspension method or the growth method. The turbidity should be verified using a nephelometer or a McFarland standard. Laboratories should periodically verify the accuracy of their inoculum preparation by comparing colony counts with expected values.

Media and Reagent Problems

The quality of the medium and reagents directly affects AST results. Mueller-Hinton agar that is too thick or too thin, that contains inhibitors, or that has an incorrect pH can produce inaccurate zone diameters. Antimicrobial discs that are expired, desiccated, or stored improperly can lose potency and produce smaller zones.

Laboratories should verify the performance of each new lot of medium and reagents before use. The quality control organisms should be tested on each new lot, and the results should fall within the acceptable ranges. Media should be stored according to manufacturer instructions and used within the recommended timeframe.

Breakpoint Interpretation Errors

Using outdated breakpoints is a common cause of AST reporting errors. Breakpoints are revised as new clinical data become available, and laboratories must update their interpretive criteria promptly. A retrospective study found that outdated CLSI breakpoints led to significant misclassification of aminoglycoside susceptibility among Enterobacterales and of piperacillin-tazobactam and tobramycin susceptibility among Pseudomonas aeruginosa (Impact of Outdated Clinical and Laboratory Standards Institute (CLSI) Breakpoint Implementation on Antimicrobial Susceptibility Interpretation: A Retrospective Analytical Study).

Laboratories should designate a person responsible for tracking breakpoint revisions and updating the laboratory's interpretive criteria. The updates should be documented, and all personnel should be trained on the revised breakpoints.

Contamination and Mixed Cultures

Contamination of the test system or the presence of mixed cultures can produce inaccurate AST results. The inoculum should be prepared from a pure culture, and the purity should be verified by subculturing the inoculum to a nonselective agar plate. If contamination is detected, the AST should be repeated from a pure culture.

Mixed cultures can produce overlapping zones of inhibition that are difficult to interpret. The laboratory should examine the purity plate and repeat the AST if more than one colony type is present.

Biosafety and Regulatory Considerations

AST involves the manipulation of potentially pathogenic microorganisms, and laboratories must follow biosafety practices to protect personnel and prevent environmental contamination.

Biosafety Practices

The World Health Organization Laboratory Biosafety Manual provides guidance on the safe handling of microorganisms in the laboratory (Laboratory Biosafety Manual). Laboratories should implement standard precautions, including hand hygiene, personal protective equipment, and safe handling of sharps. Work with organisms that pose a higher risk of transmission may require additional precautions, such as a biological safety cabinet.

AST procedures should be performed in a manner that minimizes the generation of aerosols. The inoculum preparation, plate inoculation, and zone measurement should be performed carefully to avoid splashing or spraying. Contaminated materials should be decontaminated before disposal.

Regulatory Requirements

Laboratories that perform AST for clinical purposes must comply with regulatory requirements, including laboratory accreditation and proficiency testing. The U.S. Food and Drug Administration and the Clinical and Laboratory Standards Institute are involved in the process of AST and in setting and revising breakpoints (Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists).

The Bioanalytical Method Validation Guidance from the U.S. Food and Drug Administration provides guidance on the validation of analytical methods, including those used for antimicrobial susceptibility testing in research and drug development (Bioanalytical Method Validation Guidance). Laboratories should follow the applicable regulatory requirements for their jurisdiction and testing context.

Emerging Technologies and Future Directions

The limitations of conventional AST methods have driven the development of new technologies that aim to reduce turnaround time, improve accuracy, and expand testing capabilities.

Rapid Phenotypic Methods

Rapid phenotypic methods detect bacterial growth or metabolic activity in the presence of antimicrobial agents using techniques such as mass spectrometry, flow cytometry, or microfluidics. These methods can produce results in hours instead of days, enabling earlier optimization of antimicrobial therapy.

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)-based AST is particularly promising because it can be combined with MALDI-TOF MS identification (How to accelerate antimicrobial susceptibility testing). Direct testing from positive blood cultures can provide particularly early findings, with positive blood cultures being the most suitable specimen type for rapid AST.

Microfluidic systems for AST offer the possibility to reduce detection time, as small sample and reagent volumes can be used and the detection of single cells is possible (Microfluidic Systems for Antimicrobial Susceptibility Testing). Some approaches aim to use human samples without pretreatment or pre-cultivation, which would further reduce turnaround time.

Genotypic Methods

Genotypic methods detect specific resistance genes or mutations instead of phenotypic resistance. These methods can be very rapid, but the interpretation of their clinical impact is limited because the presence of a resistance gene does not always correlate with phenotypic resistance.

Genotypic methods are most useful for detecting resistance mechanisms that are well characterized and strongly correlated with phenotypic resistance. For example, the detection of mecA in staphylococci predicts resistance to beta-lactam antimicrobials. However, genotypic methods cannot detect novel resistance mechanisms, and phenotypic methods remain necessary for definitive susceptibility categorization.

Metabolic Profiling

Metabolic profiling methods compare the metabolic activity of bacteria in the presence and absence of antimicrobial agents. Bacterial metabolism is a fast process, with bacterial cells doubling about every 20 to 30 minutes for fast-growing species, and metabolic changes can be detected before visible growth occurs (Recent Development of Rapid Antimicrobial Susceptibility Testing Methods through Metabolic Profiling of Bacteria).

These methods offer the potential for same-day AST results, but they require validation against reference methods and careful standardization. The metabolic response to antimicrobials can vary by organism and antimicrobial agent, and the interpretation of metabolic profiles requires sophisticated data analysis.

Artificial Intelligence Applications

Artificial intelligence is being applied to AST to automate zone measurement, interpret results, and predict resistance patterns. A study using the YOLO11n object detection model for automated detection and quantification of inhibition zones achieved a categorical agreement of 94.2%, with a very major error rate of 1.2% and a major error rate of 1.8% (Automatic detection and quantification of antimicrobial inhibition zones using YOLO11n with post-hoc interpretability validation).

These systems can reduce the subjectivity of zone measurement and improve the reproducibility of disk diffusion results. However, they require validation against manual measurement and must be integrated into the laboratory workflow effectively.

Professional Escalation Criteria

Laboratory professionals should escalate AST issues to supervisors, medical directors, or reference laboratories under specific circumstances. The following situations warrant escalation:

• Quality control results that fall outside the acceptable ranges and cannot be resolved by troubleshooting
• Unusual resistance patterns that suggest a new or emerging resistance mechanism
• Discrepancies between AST results and expected patterns for the organism
• Results that have major clinical implications, such as resistance to last-line antimicrobial agents
• Inability to interpret results due to technical problems or atypical growth patterns

The laboratory should have a documented procedure for escalating these issues, including the responsible personnel, the communication pathway, and the documentation requirements. The escalation should occur in a timely manner to avoid delays in patient care.

Frequently Asked Questions

What is the difference between disk diffusion and broth microdilution?

Disk diffusion measures the zone of inhibition around an antimicrobial disc on an agar plate and produces qualitative categories of susceptible, intermediate, or resistant. Broth microdilution measures the lowest concentration of an antimicrobial that inhibits visible growth in broth and produces a quantitative MIC value. Broth microdilution is the reference method for many organism-antimicrobial combinations, while disk diffusion is simpler and more flexible for routine testing.

How are AST breakpoints determined and updated?

Breakpoints are established by organizations such as the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). They are based on the MIC distribution of the organism population, pharmacokinetic and pharmacodynamic data, and clinical outcome data. Breakpoints are revised as new resistance mechanisms emerge, new antimicrobial agents are developed, and new clinical data become available. Laboratories must track breakpoint revisions and update their interpretive criteria promptly.

Why do CLSI and EUCAST sometimes report different susceptibility results?

CLSI and EUCAST may use different breakpoints for the same organism-antimicrobial combination, which can produce different interpretive categories for the same MIC value or zone diameter. The harmonization of breakpoints across Europe has reduced discrepancies, but differences remain for some agents. Laboratories must select one standard and apply it consistently, and clinicians should be aware of the standard used by their laboratory.

What quality control is required for antimicrobial susceptibility testing?

Quality control organisms with known susceptibility patterns are tested alongside clinical isolates to verify that the testing system is performing correctly. The results must fall within established quality control ranges for the test to be considered valid. Laboratories must also participate in external quality assessment programs, also known as proficiency testing, to evaluate their performance against other laboratories.

How long does antimicrobial susceptibility testing take?

Conventional phenotypic methods require 16 to 24 hours for growth and antimicrobial response, which delays the availability of results. Automated systems can produce results in 4 to 16 hours, depending on the organism and the system. Rapid AST methods using metabolic profiling, mass spectrometry, or microfluidics can produce results in hours, but they require validation and may not be available in all laboratories.

Can automated systems replace conventional AST methods?

Automated systems offer rapid results and standardized panels, but they have limitations for specific organism-drug combinations. In a study of Staphylococcus lugdunensis, the Vitek 2 automated system overestimated penicillin and oxacillin resistance compared with disc diffusion and PCR results. Laboratories should validate automated systems against reference methods and confirm unusual results with alternative methods.

What is an antibiogram and how is it used?

A cumulative antibiogram summarizes the susceptibility patterns of organisms isolated in the laboratory over a defined period, typically one year. Antibiograms are used to guide empirical antimicrobial therapy, monitor resistance trends, and identify emerging resistance problems. Age-specific antibiograms can reveal differences in susceptibility patterns between patient populations and support more targeted empirical therapy.

What should a laboratory do when AST results are discrepant with expected patterns?

The laboratory should investigate the discrepancy by reviewing the quality control results, verifying the organism identification, and repeating the AST if necessary. If the discrepancy persists, the laboratory should escalate the issue to a supervisor or medical director. Unusual resistance patterns may indicate a new or emerging resistance mechanism and should be reported to the appropriate public health authorities.

Related Diagnostic Guides

• Comparison of Disk Diffusion and Broth Microdilution for Antimicrobial Susceptibility Testing
• Disk Diffusion Method for Antimicrobial Susceptibility Testing: Protocol and Interpretation
• How to Interpret Zone Diameter Measurements in Disk Diffusion Susceptibility Testing
• Quality Control Strains for Antimicrobial Susceptibility Testing: Selection and Maintenance
• Common Sources of Error in Disk Diffusion Susceptibility Testing and How to Avoid Them

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists.. Pharmacotherapy, 2023.
• Antimicrobial susceptibility testing breakpoints and methods from BSAC to EUCAST.. The Journal of antimicrobial chemotherapy, 2016.
• Microfluidic Systems for Antimicrobial Susceptibility Testing.. Advances in biochemical engineering/biotechnology, 2022.
• How to accelerate antimicrobial susceptibility testing.. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2019.
• Cytomegalovirus.. Microbiology spectrum, 2016.
• Antimicrobial Susceptibility Testing for Staphylococcus lugdunensis.. Journal of clinical microbiology, 2022.
• Antimicrobial susceptibility testing of anaerobic bacteria: In routine and research.. Anaerobe, 2022.
• Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy.. Frontiers in cellular and infection microbiology, 2020.
• Age-Specific Antibiograms for Bacterial Meningitis Pathogens Based on Isolates Collected in a Community Laboratory.. 2026.
• Impact of Outdated Clinical and Laboratory Standards Institute (CLSI) Breakpoint Implementation on Antimicrobial Susceptibility Interpretation: A Retrospective Analytical Study.. 2026.
• Digital Infrastructure for Antimicrobial Susceptibility Testing and Surveillance: A CLSI and EUCAST-Based Model for Resource-Limited Settings.. 2026.
• Automatic detection and quantification of antimicrobial inhibition zones using YOLO11n with &lt,i&gt,post-hoc&lt,/i&gt, interpretability validation.. 2026.
• Five-year antimicrobial resistance trends and facility antibiogram at Dodoma Regional Referral Hospital, Tanzania: a retrospective study (2018-2023). 2026.
• National surveillance of antimicrobial resistance in Iran using IAMR software: A hospital-based study.. 2026.
• Performance standards for antimicrobial susceptibility testing. 2019.
• Performance standards for antimicrobial susceptibility testing. 2001.
• Rapid Antimicrobial Susceptibility Testing Methods for Blood Cultures and Their Clinical Impact. Frontiers in Medicine, 2021.
• Conventional methods and future trends in antimicrobial susceptibility testing. Saudi Journal of Biological Sciences, 2023.
• Recent Development of Rapid Antimicrobial Susceptibility Testing Methods through Metabolic Profiling of Bacteria. Antibiotics, 2021.
• Advanced Phenotypic Antimicrobial Susceptibility Testing Methods. Advanced Techniques in Diagnostic Microbiology Volume 1 Techniques Third Edition, 2018.
• Factors affecting the antimicrobial susceptibility testing of bacteria by disc diffusion method. Medicina, 2008.
• Same day identification and full panel antimicrobial susceptibility testing of bacteria from positive blood culture bottles made possible by a combined lysis-filtration method with MALDI-TOF VITEK mass spectrometry and the VITEK2 system. Plos One, 2014.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.